, Columnist
The U.S. Is Doing Too Little to Monitor Paxlovid Use
Prescriptions for Pfizer’s Covid-19 antiviral are skyrocketing, but it remains unclear how much the drug helps vaccinated patients — especially if they are at low risk of serious disease.
Doctors have questions about Covid antivirals.
Photographer: Kobi Wolf/BloombergThis article is for subscribers only.
Paxlovid, Pfizer’s antiviral treatment for Covid-19, is turning out to be one of the most successful new drugs in pharma history. Prescriptions have increased tenfold since February, and the five-day pill pack accounts for nearly 90% of the Covid oral-antiviral market.
Based on committed contracts from governments around the world, sales of the drug will reach $22 billion this year, Pfizer affirmed on Tuesday.